RxDoctor Payments Data

Maxwell Krem, MD

Hematology & Oncology · Columbia, MONPI 1346300324

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $750 of the $878 with a category attached, or 85.4%. 9 manufacturers reported payments, led by AstraZeneca at 25.6% of the total. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.

$878in general payments, 2019–2025

Across 20 payments — averaging $43.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$224
  • Takeda Pharmaceuticals U.S.A., Inc.$157
  • Gilead$152
  • Jazz Pharmaceuticals Inc.$105
  • Astellas Pharma US Inc$100
  • Genentech, Inc.$41
  • plus $99 from 3 others
$37,130in research payments, 2019–2025

Across 5 payments — averaging $7426.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$24K
  • Novartis$13K
  • F. Hoffmann-la Roche AG$450

What the payments were for

  • Food & beverage$75085%
  • Education$12815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$878 in reported general payments places this provider in the 40th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$6,386
Medicare patients
23
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →